期刊文献+

Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation 被引量:5

Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation
下载PDF
导出
摘要 New nucleos(t)ide analogues(NAs) with high genetic barrier to hepatitis B virus(HBV) resistance(such as entecavir, tenofovir) have improved the prognosis of patients with HBV decompensated cirrhosis and have prevented HBV recurrence after liver transplantation(LT). NAs are considered the most proper approach for HBV infection in patients under renal replacement therapy but their doses should be adjusted according to the patient's creatinine clearance. In addition, physi-cians should be aware of the potential nephrotoxicity. However, patients with chronic hepatitis C and decom-pensated cirrhosis can receive only one therapeutic option before LT, as well as for Hepatitis C virus(HCV) recurrence after LT, which is the combination of sub-cutaneous Peg-IFN and ribavirin. Generally, therapy for HCV after renal transplantation should be avoided. Although the optimal antiviral therapy for HCV infec-tion has not been established, attention has turned to a new, oral direct acting antiviral treatment which marks a promising strategy in prognosis and in amelioration of these diseases. New nucleos(t)ide analogues(NAs) with high genetic barrier to hepatitis B virus(HBV) resistance(such as entecavir, tenofovir) have improved the prognosis of patients with HBV decompensated cirrhosis and have prevented HBV recurrence after liver transplantation(LT). NAs are considered the most proper approach for HBV infection in patients under renal replacement therapy but their doses should be adjusted according to the patient’s creatinine clearance. In addition, physi-cians should be aware of the potential nephrotoxicity. However, patients with chronic hepatitis C and decom-pensated cirrhosis can receive only one therapeutic option before LT, as well as for Hepatitis C virus(HCV) recurrence after LT, which is the combination of sub-cutaneous Peg-IFN and ribavirin. Generally, therapy for HCV after renal transplantation should be avoided. Although the optimal antiviral therapy for HCV infec-tion has not been established, attention has turned to a new, oral direct acting antiviral treatment which marks a promising strategy in prognosis and in amelioration of these diseases.
出处 《World Journal of Hepatology》 CAS 2014年第5期315-325,共11页 世界肝病学杂志(英文版)(电子版)
关键词 Liver TRANSPLANTATION KIDNEY transplanta-tion HEPATITIS C HEPATITIS B RECURRENCE Liver transplantation Kidney transplantation Hepatitis C Hepatitis B Recurrence
  • 相关文献

参考文献18

  • 1Matthew D Sadler,Carla S Coffin,Samuel S Lee.Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis[J]. Expert Opinion on Pharmacotherapy . 2013 (10)
  • 2Catherine AM Stedman.Current prospects for interferon‐free treatment of hepatitis C in 2012[J]. J Gastroenterol Hepatol . 2012 (1)
  • 3H. L.Y. Chan,Y. C. Chen,E. J. Gane,S. K. Sarin,D. J. Suh,T. Piratvisuth,B. Prabhakar,S. G. Hwang,G. Choudhuri,R. Safadi,T. Tanwandee,A. Chutaputti,C. Yurdaydin,W. Bao,C. Avila,A. Trylesinski.Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment‐na?ve patients with HBV‐related decompensated cirrhosis[J]. Journal of Viral Hepatitis . 2012 (10)
  • 4A.Fraser,A.Austin,G. R.Foster,P. C.Hayes,P. R.Mills,S. D.Ryder.UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients[J]. Aliment Pharmacol Ther . 2012 (6)
  • 5DidierSamuel.Hepatitis C virus treatment pre‐ and post‐liver transplantation[J]. Liver Int . 2011
  • 6E. Jenny Heathcote,Patrick Marcellin,Maria Buti,Edward Gane,Robert A. De Man,Zahary Krastev,George Germanidis,Samuel S. Lee,Robert Flisiak,Kelly Kaita,Michael Manns,Iskren Kotzev,Konstantin Tchernev,Peter Buggisch,Frank Weilert,Oya Ovunc Kurdas,Mitchell L. Shiffman,Huy Trinh,Selim Gurel,Andrea Snow–Lampart,Katyna Borroto–Esoda,Elsa Mondou,Jane Anderson,Jeff Sorbel,Franck Rousseau.Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B[J]. Gastroenterology . 2011 (1)
  • 7Phuong‐ThuPham,Phuong‐AnhPham,Phuong‐ChiPham,SefaliParikh,GabrielDanovitch.Evaluation of Adult Kidney Transplant Candidates[J]. Seminars in Dialysis . 2010 (6)
  • 8European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B[J]. Journal of Hepatology . 2009 (2)
  • 9Yun-Fan Liaw,Nancy Leung,Jia-Horng Kao,Teerha Piratvisuth,Edward Gane,Kwang-Hyub Han,Richard Guan,George K. K. Lau,Stephen Locarnini.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update[J]. Hepatology International . 2008 (3)
  • 10George V Papatheodoridis,Spilios Manolakopoulos,Geoffrey Dusheiko,Athanasios J Archimandritis.Therapeutic strategies in the management of patients with chronic hepatitis B virus infection[J]. The Lancet Infectious Diseases . 2008 (3)

共引文献11

同被引文献14

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部